Expert Interview
A Second Opinion: Discussing the recent approval of JNJs Opsynvi for the treatment of Pulmonary Arterial Hypertension
Ticker(s): JNJInstitution: Somerset Pulmonary
- Pulmonologist with the Somerset Pulmonary & Sleep Medicine Center in practice for over 3 decades.
- treats Approximately 680 patients per year with COPD
- familiar with the Phase 3 BOREAS trial of dupilumab in COPD patients and was happy to see data supporting the use of a biologic response modifier in patients with COPD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
